BDBM251910 US10065961, Compound 8::US10683295, Compound 8::US10941151, Compound 8::US9475814, 8

SMILES C[C@H]1N(CCn2c1nnc2-c1csc(C=C)n1)C(=O)c1ccc(cc1)-c1ccccc1

InChI Key InChIKey=JNFILNQMEWMOSR-MRXNPFEDSA-N

Data  4 KI  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 251910   

TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251910(US10065961, Compound 8 | US10683295, Compound 8 | ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251910(US10065961, Compound 8 | US10683295, Compound 8 | ...)
Affinity DataKi:  7nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251910(US10065961, Compound 8 | US10683295, Compound 8 | ...)
Affinity DataKi:  7nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251910(US10065961, Compound 8 | US10683295, Compound 8 | ...)
Affinity DataKi:  7nMAssay Description:The antagonist activity of compounds of the invention is measured following pre-incubation (3 minutes) of the compound with the cells, followed by ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251910(US10065961, Compound 8 | US10683295, Compound 8 | ...)
Affinity DataIC50:  7nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM251910(US10065961, Compound 8 | US10683295, Compound 8 | ...)
Affinity DataIC50:  7nMAssay Description:The antagonist activity of compounds of the invention is measured following pre-incubation (3 minutes) of the compound with the cells, followed by ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent